

# Carolina S Ilkow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8850817/publications.pdf>

Version: 2024-02-01

40  
papers

1,514  
citations

430442

18  
h-index

344852

36  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1866  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection. <i>Molecular Therapy</i> , 2022, 30, 1885-1896.	3.7	16
2	Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 507-521.	2.0	7
3	Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. <i>Nature Communications</i> , 2022, 13, 1898.	5.8	16
4	Identification of FDA-approved Bifonazole as SARS-CoV-2 blocking agent following a bioreporter drug screen. <i>Molecular Therapy</i> , 2022, , .	3.7	5
5	Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2268.	1.8	24
6	Personalized oncology and BRAF K601N melanoma: model development, drug discovery, and clinical correlation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1365-1378.	1.2	2
7	A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion. <i>Nanomaterials</i> , 2021, 11, 807.	1.9	7
8	SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. <i>Biosensors and Bioelectronics</i> , 2021, 180, 113122.	5.3	21
9	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry. <i>Molecular Therapy</i> , 2021, 29, 1984-2000.	3.7	19
10	Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	0
11	Oncolytic Virus Immunotherapy. <i>Cancers</i> , 2021, 13, 3672.	1.7	4
12	Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic. <i>ACS Nanoscience Au</i> , 2021, 1, 15-37.	2.0	9
13	Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	1
14	Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 102-114.	3.2	7
15	Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis. <i>Cancers</i> , 2020, 12, 2042.	1.7	14
16	Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization. <i>Membranes</i> , 2020, 10, 215.	1.4	20
17	Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses. <i>Methods in Molecular Biology</i> , 2020, 2058, 271-284.	0.4	0
18	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. <i>Molecular Therapy - Oncolytics</i> , 2019, 14, 179-187.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Dimethyl fumarate potentiates oncolytic virotherapy through NF- $\kappa$ B inhibition. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	44
20	Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference. , 2018, 6, 62.		8
21	Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy. <i>EBioMedicine</i> , 2018, 31, 17-24.	2.7	115
22	A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma. <i>Cancer Cell</i> , 2017, 32, 133-134.	7.7	13
23	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16027.	2.0	11
24	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. <i>Cancer Cell</i> , 2015, 28, 210-224.	7.7	77
25	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. <i>Nature Communications</i> , 2015, 6, 6410.	5.8	42
26	Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques. <i>Molecular Therapy</i> , 2015, 23, 1066-1076.	3.7	65
27	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. <i>Nature Medicine</i> , 2015, 21, 530-536.	15.2	118
28	Maraba MG1 Virus Enhances Natural Killer Cell Function via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease. <i>Molecular Therapy</i> , 2014, 22, 1320-1332.	3.7	60
29	From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer. <i>PLoS Pathogens</i> , 2014, 10, e1003836.	2.1	61
30	Smac mimetics and innate immune stimuli synergize to promote tumor death. <i>Nature Biotechnology</i> , 2014, 32, 182-190.	9.4	104
31	Phosphorylation and membrane association of the Rubella virus capsid protein is important for its anti-apoptotic function. <i>Cellular Microbiology</i> , 2014, 16, 1201-1210.	1.1	9
32	Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans. <i>Cancer Research</i> , 2013, 73, 1265-1275.	0.4	193
33	The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers. <i>Molecular Therapy</i> , 2012, 20, 749-758.	3.7	231
34	Achieving efficient systemic delivery of oncolytic Vaccinia virus. <i>Immunobiology</i> , 2012, 217, 1135.	0.8	0
35	The Rubella Virus Capsid Is an Anti-Apoptotic Protein that Attenuates the Pore-Forming Ability of Bax. <i>PLoS Pathogens</i> , 2011, 7, e1001291.	2.1	33
36	Rubella virus capsid protein: a small protein with big functions. <i>Future Microbiology</i> , 2010, 5, 571-584.	1.0	11

#	ARTICLE	IF	CITATIONS
37	The Rubella Virus Capsid Protein Inhibits Mitochondrial Import. <i>Journal of Virology</i> , 2010, 84, 119-130.	1.5	34
38	Modulation of signaling pathways by RNA virus capsid proteins. <i>Cellular Signalling</i> , 2008, 20, 1227-1236.	1.7	19
39	Rubella Virus Capsid Protein Interacts with Poly(A)-Binding Protein and Inhibits Translation. <i>Journal of Virology</i> , 2008, 82, 4284-4294.	1.5	53
40	Analyses of Phosphorylation Events in the Rubella Virus Capsid Protein: Role in Early Replication Events. <i>Journal of Virology</i> , 2006, 80, 6917-6925.	1.5	21